Meeting Report

New Drug Updates in Hematologic Malignancies: CAR-T, Targeted Therapeutics, and Other Agents

Presented by R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA

Emory University and Winship Cancer Institute, Atlanta, Georgia

Presenter’s disclosures of conflicts of interest are found at the end of this article.


J Adv Pract Oncol 2018;9(3):282–286 | https://doi.org/10.6004/jadpro.2018.9.3.3 | © 2018 Harborside™


  

ABSTRACT

FDA approvals for hematologic malignancies from 2016 to 2017 can be grouped in three themes: personalized small molecules, immunotherapies, and new formulations or modes of delivery for conventional agents. The unique profiles of these drugs, including that of CAR-T cell therapy, are summarized.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.